Brief Summary
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advancedat a late stage, far along or Metastatic Solid Tumors.
Intervention / Treatment
- Drug: YH32367
Inclusion Criteria:
[Dosethe amount of medication taken Escalation Part]
- Pathologically confirmed HER2-positive
- Mandatory provision of tumor tissuea group of cells that work together to perform a function sample
[Dose Expansion Part]
- Patients who have at least one measurable lesion
- Mandatory provision of tumor tissue sample
- Cohort 1: Pathologically confirmed HER2-positive biliary tract cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs
- Cohort 2: Pathologically confirmed HER2-positive metastatic solid tumor malignancy other than breast and gastric or gastroesophageal junction adenocarcinomacancer arising from mucus-producing glands in organs and biliary tract cancer